310 related articles for article (PubMed ID: 34638325)
1. Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives.
Varnier R; Sajous C; de Talhouet S; Smentek C; PĂ©ron J; You B; Reverdy T; Freyer G
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638325
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
Sammons S; Sedrak MS; Kimmick GG
Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
[TBL] [Abstract][Full Text] [Related]
4. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
Krop I; Ismaila N; Andre F; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Wolff AC; Stearns V
J Clin Oncol; 2017 Aug; 35(24):2838-2847. PubMed ID: 28692382
[TBL] [Abstract][Full Text] [Related]
5. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
6. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
Kittaneh M; Badve S; Caldera H; Coleman R; Goetz MP; Mahtani R; Mamounas E; Kalinsky K; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Traina T; Vogel C
Clin Breast Cancer; 2020 Jun; 20(3):183-193. PubMed ID: 32014370
[TBL] [Abstract][Full Text] [Related]
7. Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Ovcaricek T; Takac I; Matos E
Radiol Oncol; 2019 Sep; 53(3):285-292. PubMed ID: 31553709
[TBL] [Abstract][Full Text] [Related]
8. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
9. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of gene-expression signatures in early stage breast cancer.
Kwa M; Makris A; Esteva FJ
Nat Rev Clin Oncol; 2017 Oct; 14(10):595-610. PubMed ID: 28561071
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer gene expression signatures: development and clinical significance-a narrative review.
Li S; Yu X; Xu Y
Transl Breast Cancer Res; 2023; 4():7. PubMed ID: 38751471
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer.
Iwamoto T; Kajiwara Y; Zhu Y; Iha S
Chin Clin Oncol; 2020 Jun; 9(3):27. PubMed ID: 32192349
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
15. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel
J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
[TBL] [Abstract][Full Text] [Related]
16. Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available evidence and clinical implications.
Griguolo G; Bottosso M; Vernaci G; Miglietta F; Dieci MV; Guarneri V
Cancer Treat Rev; 2022 Jan; 102():102323. PubMed ID: 34896969
[TBL] [Abstract][Full Text] [Related]
17. Open questions and controversies in the systemic treatment of breast cancer.
Barrios CH; Reinert T
Curr Opin Oncol; 2021 Nov; 33(6):591-596. PubMed ID: 34419955
[TBL] [Abstract][Full Text] [Related]
18. Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group.
Licata L; Cosentini D; De Sanctis R; Iorfida M; Caremoli ER; Vingiani A; Simoncini EL; Pruneri G; Munzone E; Bianchini G; Zambelli A; Tondini C
Front Oncol; 2023; 13():1081885. PubMed ID: 36950554
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
20. Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
Matikas A; Foukakis T; Swain S; Bergh J
Ann Oncol; 2019 Jul; 30(7):1044-1050. PubMed ID: 31131397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]